Three posters presented on September 10, 2017, at the European Society for Medical Oncology (ESMO) 2017 meeting in Madrid, Spain, covered research on 2 proposed pegfilgrastim biosimilars and evaluated the use of filgrastim in oncology practice.
Three posters presented on September 10, 2017, at the European Society for Medical Oncology (ESMO) 2017 meeting in Madrid, Spain, covered research on 2 proposed pegfilgrastim biosimilars and evaluated the use of filgrastim in oncology practice.
In their presentation, Paul Cornes, MD, and Andriy Krendyukov conclude that physicians and payers need to be aware that Health Technology Assessment (HTA)—based decisions require constant reevaluation, especially following the launch of biosimilar alternatives to biologic medications, because biosimilars can transform healthcare. “This explains the first inclusion of filgrastim in the World Health Organization (WHO) essential drug list for cancer more than 20 years after its original approval in 1991,” they note.1
In their value evaluation of the evolution of the granulocyte colony stimulating factor filgrastim in oncology practice, the 2 researchers conducted a literature search of 25 systematic reviews and 55 economic evaluations of filgrastim to examine its value over time, as new evidence for risks and benefits of use emerged and the economics of the drug changed. HTAs initially suggested a low value for filgrastim because of its high cost and (at the time) no evidence of significant gain in overall survival (OS). However, more recent meta-analyses of placebo-controlled randomized clinical trial data show absolute overall survival gains of 3.2% (95% CI, 2.1% to 4.2%) resulting from filgrastim support of cytotoxic chemotherapy and falling costs due to biosimilar competition.
In their poster, Karsten Roth, PhD, and coworkers demonstrated the comparability of Cinfa Biotech’s proposed pegfilgrastim biosimilar, B12019, with reference drug Neulasta in 2 highly sensitive clinical study settings in 172 and 96 healthy volunteers.2
The pharmacokinetic comparability of B12019 and Neulasta was demonstrated at the clinical dose of 6 mg, and the pharmacodynamic comparability of B12019 and Neulasta was shown at the clinical dose of 6 mg and the reduced dose of 3 mg. The researchers reported that the safety and immunogenicity profile of B12019 did not show any clinically meaningful differences to Neulasta.
K. Horvat-Karajz and colleagues demonstrated the therapeutic equivalence and similar safety profiles in clinical trials comparing RGB-02 (Gedeon Richter’s proposed pegfilgrastim biosimilar to reference Neulasta) as once-per-cycle administration in their poster presentation.3 The researchers concluded that RGB-02 can provide a biosimilar alternative for the prevention of neutropenia.
Their randomized, comparative, double-blind, multicenter study evaluated the efficacy and safety of RGB-02 compared with Neulasta in 239 breast cancer patients receiving up to 6 cycles of cytotoxic docetaxel and doxorubicin, and a once-per-cycle injection of a fixed 6-mg dose of pegfilgrastim. The duration of severe neutropenia (defined as an absolute neutrophil count [ANC] of less than 0.5x109/L) in cycle 1 was the primary endpoint; secondary endpoints included incidence and duration of severe neutropenia, incidence of febrile neutropenia, time to ANC recovery, depth of ANC nadir, and safety outcomes.
The mean duration of severe neutropenia in cycle 1 was 1.7 days for the biosimilar RGB-02 and 1.6 days for the reference drug. Therapeutic equivalence was established, they said, as the results were within the predefined range of ±1 day. The incidence of severe neutropenia decreased from cycle 1 to cycle 2 in both groups, with no statistically significant differences: from 84.6% (99 patients) to 54.1% (60 patients) for RGB-02 and from 77.0% (87 patients) to 43.7% (45 patients) in the comparator group. Both groups were similar regarding mean time to ANC recovery with 3.4 ±1.88 days during cycle 1. Safety profiles were comparable between groups.
References
1. Cornes P, Krendyukov A. The revolution of value with filgrastim in oncology. Presented at the European Society for Medical Oncology 2017 Congress; September 8-12, 2017; Madrid, Spain. Abstract 1126P. cslide.ctimeetingtech.com/library/esmo/browse/search/51E#2Bb4e.
2. Roth K, Wessels H, Hoefler, J, et al. Pharmacokinetic and pharmacodynamic comparability of B12019: a proposed pegfilgrastim biosimilar. Presented at the European Society for Medical Oncology 2017 Congress; September 8-12, 2017; Madrid, Spain. Abstract 1573P. cslide.ctimeetingtech.com/library/esmo/browse/search/51E#2Bb4e.
3. Horvatz-Karajz K, Grecea D, Smakal M, et al. Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind, phase 3 clinical study versus reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin. Presented at the European Society for Medical Oncology 2017 Congress; September 8-12, 2017; Madrid, Spain. Abstract 1574P. cslide.ctimeetingtech.com/library/esmo/browse/search/51E#2Bb4e.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.